Indications
Therapeutic Asset Ratings
3,186 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Autologous, Engineered T Cells Targeting Tp53 R248Q
Colorectal Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Early P1
C
(33)
Egfr/B7H3 Car-T
Triple-Negative Breast Carcinoma
Second Affiliated Hospital of Guangzhou Medical University
Early P1
C
(33)
Fast Car T Cells
Neoplasm
Shanghai Cell Therapy Group Co.,Ltd
Early P1
C
(33)
gc203 til
Cancer
Shanghai Juncell Therapeutics
Early P1
C
(33)
gc203 til
Pancreatic Neoplasm
Shanghai Juncell Therapeutics
Early P1
C
(33)
Gprc5D-Car-T
Plasma Cell Myeloma
Guangzhou Bio-gene Technology Co., Ltd
Early P1
C
(33)
gt316
Neoplasm
Grit Biotechnology
Early P1
C
(33)
Hs-It101
Cancer
The Affiliated Hospital of Qingdao University
Early P1
C
(33)
Hs-It101
Breast Cancer
The Affiliated Hospital of Qingdao University
Early P1
C
(33)
ibr900 cell
Cancer
Beijing Boren Hospital
Early P1
C
(33)
im92 car-t cells
Cancer
Beijing Immunochina Medical Science & Technology Co., Ltd.
Early P1
C
(33)
im92 car-t cells
Pancreatic Neoplasm
Beijing Immunochina Medical Science & Technology Co., Ltd.
Early P1
C
(33)
im96 car-t cells
Cancer
Beijing Immunochina Medical Science & Technology Co., Ltd.
Early P1
C
(33)
ksh01
Neoplasm
TCRx Therapeutics Co.Ltd
Early P1
C
(33)
Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-Til)
Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early P1
C
(33)
nk521 cell
Cancer
Base Therapeutics (Shanghai) Co., Ltd.
Early P1
C
(33)
nk521 cell
Ovarian Cancer
Base Therapeutics (Shanghai) Co., Ltd.
Early P1
C
(33)
nkg2d chimeric antigen receptor nk cell
Plasma Cell Myeloma
Changzhou No.2 People's Hospital
Early P1
C
(33)
rd14-01 cell
Neoplasm
Shen Lin
Early P1
C
(33)
Senl103
Plasma Cell Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
Early P1
C
(33)
Tc-G203 Cells Treatment
Hepatocellular Carcinoma
Beijing GoBroad Hospital
Early P1
C
(33)
TIL
Cancer
Shanghai Juncell Therapeutics
Early P1
C
(33)
Allo-Quadcar01-T
Leukemia
AvenCell Therapeutics, Inc.
P1/2
C
(33)
Armored And Gpc3-Targeted Autologous Car T-Cell
Hepatocellular Carcinoma
Shanghai AbelZeta Ltd.
P1/2
C
(33)
gpc3-car-t cells
Cutaneous Neuroendocrine Carcinoma
Sotio Biotech Inc.
P1/2
C
(33)
Showing 2526 to 2550 of 3,186 assets
Previous
Page 102 of 128
Next
